ONCO: Oncopeptides AB (publ) - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

Oncopeptides AB (publ)

SWE:ONCO

SummaryFactSheetFinancial
Price
kr1.60
Loss Chance
50.9%
3.28JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Biotechnology
4 / 30
Health Care
18 / 105
Sweden
?
156 / 618
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Related
Biovica International AB (publ)
SWE:BIOVIC B
3.66
kr0.45
100.00%
Bonesupport Holding AB (publ)
SWE:BONEX
6.92
kr219.40
320.57%
Devyser Diagnostics AB (publ)
SWE:DVYSR
4.48
kr61.80
150.38%
ExpreS2ion Biotech Holding AB (publ)
SWE:EXPRS2
1.33
kr1.40
100.00%
Medivir AB (publ)
SWE:MVIR
1.95
kr1.75
100.00%
Jitta Factors
Growth Opportunity (56)
Recent Business Performance (74)
Financial Strength (26)
Return to Shareholders (13)
Competitive Advantage (51)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Operating MarginInconsistent
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
3.28
100.00%
2.37
111.17%
2.89
158.61%
Biotechnology
3.66
100.00%
6.92
320.57%
4.48
150.38%
COMPANY DESCRIPTION
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for with an alkylating payload, developed for the treatment of adult patients with multiple myeloma. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic metabolites, which lead to an enrichment in cancer cells. It offers OPD5, OPDC3, and Gliopep for the treatment of hematological or solid tumors, and glioblastoma. The company also provides Small Polypeptide based Killer Engagers (SPiKE) platform that is designed to bind to both NK-cells and specific targets on various cancer cells. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
www.oncopeptides.com/sv
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.